Al was diagnosed with Ph+ CML in chronic phase in 1997, before the first tyrosine kinase inhibitor (TKI) was available to treat the disease. He provides insights about being open to discussing the use of different medications with your doctor if you are not meeting your treatment goals or if side effects are becoming intolerable.
Please note, Al cannot provide clinical advice or counseling. For medical questions, speak with your doctor.
Al is an actual patient who has been compensated by Novartis Pharmaceuticals Corporation for participating in the SCEMBLIX Peers program.
Would you say CML is a “good cancer?”
What results have you seen with SCEMBLIX?
What is SCEMBLIX and what are the possible side effects?
Get the perspective of another SCEMBLIX Peer.
Hear about Lynne's Experience
